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ABSTRACT 
 
Coxsackievirus type B (CVB3) is one of the six serotypes of the Coxsackievirus family 
of non-enveloped, linear, and positive-sense single-stranded RNA viruses.  It is a pathogenic 
enterovirus that belongs to the same genus as the notable pathogen poliovirus. CVB3 can cause a 
range of illnesses from a fever to gastrointestinal distress but is most noteworthy for the ability to 
cause viral myocarditis, a swelling of the heart muscle. Coxsackievirus, like all RNA viruses, 
tends to develop mutations rapidly due to its error prone polymerase and lack of proofreading 
activity. These mutations can be advantageous for the virus, allowing it to develop traits that 
enhance replication and pathogenesis. Due to its major clinical importance and a lack of 
available vaccine and antivirals, there is an impetus to identify effective antivirals against CVB3. 
In that regard, the virus’ ability to mutate poses a major obstacle to successful antiviral treatment 
and must be explored further to better understand the mechanisms of antiviral resistance and 
improve drug development. 
 Polyamines are small positively charged molecules that are present in all cells and have 
crucial roles in processes such as transcription, translation, DNA replication and signaling. They 
are also fundamental to a virus’ ability to infect a host. When drugs that diminish polyamines are 
added to cells, the virus’ ability to replicate tapers. One drug that acts in this way is 
difluoromethylornithine (DFMO), which diminishes the production of polyamines by inhibiting 
the first step in polyamine synthesis: the conversion of ornithine to putrescine. In order to better 
understand how CVB3 could evolve resistance to antiviral treatments, CVB3 was serially 
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passaged in the presence of DFMO.  The resultant mutations that arose in CVB3 may correlate 
with its ability to infect a host who is undergoing antiviral therapy.  
Passaging CVB3 in the presence of DFMO illuminated 3 mutations:  VP3 – 234R, which is a site 
in the viral capsid; 2A – Q29K and 3C- Q52R both of which are sites in viral proteases. These 
proteases are crucial for multiple stages of infection including protein processing and packaging. 
Due to the vital importance of the viral proteases, these mutations and their seeming tie with 
polyamines, the focus of this study will revolve around these mutations. From these initial 
findings, we hypothesize that polyamines modulate viral protease activity and CVB3 gains 
resistance to polyamine depletion via mutation of its protease(s).  
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CHAPTER ONE: BACKGROUND 
Literature Review 
Coxsackievirus Type B3 (CVB3) 
   Coxsackievirus Type B3 (CVB3) is a member of the Picornaviridae family of the enterovirus 
genus. Members of this family of viruses are non-enveloped and have a single stranded, positive 
 sense RNA genome, and notable members include poliovirus and enterovirus 711,2. CVB3, along  
with other enteroviruses, are spread via the fecal-oral route of transmission and can be found  
globally1,3. CVB3 infections occur frequently during the late summer months, as is the case with  
most enteroviruses 4. It is thought that this is due to swimming being extremely common in the  
summer months and that CVB3 can survive in environmental conditions, especially warm water,  
for extended periods of time5,6. Although infection with CVB3 is relatively mild, the wide scope, 
 its use as a model system, and its ability to cause severe disease makes it a virus worth studying.  
Clinical Outcomes of CVB3  
 Typical CVB3 infections are self-limiting and typically present with a fever and 
gastrointestinal distress. However, CVB3 infection can progress to more serious conditions 
including myocarditis and endocarditis, Burnholm syndrome, and can also cause aseptic 
meningitis if the virus enters the central nervous system 2,7,8. Myocarditis is an inflammation of 
the heart muscle which can either be caused by active viral replication, as the virus is able to 
persist in cardiac tissue9, or from the immune response associated with clearing an active 
infection9,10. Myocarditis can lead to cardiomyopathy and cardiac failure which can result in 
permanent heart damage or even death11,12. Burnholm disease, also known as epidemic
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 pleurodynia, can cause chest and muscle pain. This presentation is associated with an active 
infection, which usually clears by itself, but can persist for up to 3 weeks 7,13. Lastly, CVB3 is 
associated with aseptic meningitis, which is an inflammation of the meninges, a membrane 
covering the brain and spinal cord. 
 Epidemiologically, it is important to note is that CVB3, like all enteroviruses, spikes in the 
number of cases reported during the late summer months.  Historically, this trend was also seen 
with poliovirus in the 1950s, presumably due to the increase in people swimming in infected 
water4,6. When considering how common CVB3 infection is, its ability to cause serious illness, 
and there being no current vaccine or antiviral treatment, novel antivirals are crucially needed in 
order to control infection.  
Traditional Treatment of CVB3 
Traditionally, due to a lack of vaccine or antivirals, CVB3 treatment is palliative. Typical 
treatment of CVB3, if symptoms are mild, include hydration and common over-the-counter cold 
medications. If an infection becomes more serious, such as myocarditis or aseptic meningitis, 
then the treatment is tailored to those conditions. In many cases myocarditis improves on its 
own, and treatment involves focusing on the symptoms14. If the myocarditis is serious, 
potentially including heart failure or arrhythmias, doctors will prescribe medication in order to 
reduce the chances of blood clots forming in the heart 15. In more severe cases, an aggressive 
treatment regimen is followed such as inserting devices or balloon pumps 15. In the case of 
aseptic meningitis, the illness normally clears on its own and standard viral care procedures are 
followed such as rest and hydration16.  
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Polyamines and Cellular Functions  
 
 Polyamines are small positively charged molecules that are present in all cells. In 
eukaryotic cells there are three main polyamines, all produced by a single synthetic pathway 17,18. 
In mammalian cells this pathway starts at ornithine which gets converted to putrescine via 
ornithine decarboxylase (ODC1), the rate limiting step in the polyamine synthesis pathway17–20. 
From there, putrescine is converted into spermidine by spermidine synthase (SRM) and 
spermidine is converted into spermine via spermine synthase (SMS). Spermidine and spermine 
can also go through extra metabolic processes by spermidine/spermine acetyltransferase 1 
(SAT1) which adds an acetyl group to these polyamines, neutralizing the charge and marking 
them for export. Subsequently, acetylspermine and acetylspermidine can also go through 
polyamine oxidase (PAOX) action which converts spermine back to spermidine and spermidine 
back to putrescine17,18,20. This synthesis pathway is tightly regulated in cells, and is vitally 
important to overall cell health. A complete overview of the polyamine synthesis pathway can be 
seen in Figure 120. Polyamines play roles in protein synthesis, membrane interactions, protein-
RNA interactions, RNA structure and gene expression among other functions, making the 
process of polyamine synthesis crucial for virtually all steps in a cells lifecycle 17,18,21–24.  
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Figure 1. Polyamine Synthesis Pathway. Image adapted and modified from Wesley et. al. 
(2013)20. Permissions obtained from Wesley et. al.  
 
Polyamines and Viral Infectivity 
 
 Not only are polyamines important for eukaryotic cells, they are also vital for viral 
infectivity17. Polyamines play multiple roles in the viral lifecycles, suggesting a crucial role in 
the virus’ ability to infect a host 17. Polyamines are important for genome packaging in DNA 
viruses, where viruses use polyamines to balance charge. 17,25–27  This has also been shown for 
RNA viruses. Polyamines are also important for DNA-dependent RNA polymerization in 
vaccinia virus and have been shown to impact DNA polymerase in herpes simplex virus (HSV) 
17,28,29. Genome replication as well as viral protein translation have also been shown to rely on 
polyamines in both RNA and DNA viruses 17,30,31. Polyamine-depleting drugs on viruses such as 
chikungunya (CHIKV) have been shown as very potent, having effects on viral RNA 
polymerase, decreased overall viral translation and reduction in infectious virus produced 17,31,32. 
Interestingly, vaccinia virus appears to stimulate polyamine synthesis upon infection, by 
upregulating ODC1 activity17. While polyamines have already been shown to be important for 
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DNA and RNA viruses, we are uncovering more functions for polyamines in viral replication 
rapidly 17,31–38.  
DFMO and DENSpm  
 Due to the immense importance of polyamines in viral infectivity, blocking polyamine 
production can block viral infectivity. There are two drugs that can effectively block polyamine 
synthesis: difluoromethylornithine (DFMO) and N1,N11-diethylnorspermine (DENSpm). The 
former was originally developed as a cancer therapeutic and, has recently been repurposed as an  
FDA-approved treatment of trypanosomiasis or african sleeping sickness 39–42. DFMO 
irreversibly binds to the active site of ODC1, which is the rate limiting enzyme in the polyamine 
synthesis pathway 17. DENSpm, on the other hand, has a different mechanism of action. As a 
long carbon chain with a positive charge, DENSpm activates SAT1, depleting polyamines by 
neutralizing their charge and marking them for export 17. Both of these drugs and how they affect 
the polyamine synthesis pathway can be seen in Figure 2 below17, where DFMO and DENSpm 
are boxed in red.  DENSpm is also currently in clinical trials for cancer treatment and is shown 
to be an effective polyamine inhibitor 22. In 2016, it was discovered that DFMO and DENSpm 
also have potent antiviral effects against a variety of RNA viruses32. These two drugs thus 
represent promising candidates in antiviral research and may be the sites of viral resistance 
development.  
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Figure 2. Polyamine Synthesis Pathway and Its Inhibitors. The complete polyamine synthesis 
pathway and its inhibitors. Specific inhibitors are boxed in red; those represent the drugs that we 
utilized throughout the course of this work. Image adapted and Modified from Mounce et. al. 
(2017)17. Permissions obtained from Mounce et. al. 
 
RNA Virus Evolution  
 RNA viruses have a propensity to develop mutations along their genome with great ease, 
this is due to their error-prone RNA-dependent RNA polymerase and lack of proof-reading 
activity, meaning that RNA viral evolution can happen at an accelerated rate 43. This 
susceptibility to mutations has been well documented in RNA viruses, and mutations can happen 
even through passaging in normal infection conditions44–46. Passaging involves successive 
rounds of viral infection in typically unfavorable condition, such as drug-treated cells or in a cell 
type a virus doesn’t normally infect, where multiple rounds of passaging induces a virus has to 
adapt its genome in order to survive47,48. The mutations that may arise will give some indication 
as to what point in the viral life cycle these unfavorable conditions are affecting. Due to this 
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phenomenon, whenever a new antiviral is proposed it is important to know how a virus will 
adapt to this new condition. 
Enterovirus Life Cycle 
 
 The basic lifecycle of enteroviruses is outlined below in Figure 3 1. First, the virus binds 
to a cell, enters (viral uptake), and releases its RNA genome. The viral RNA is then translated 
into a large polyprotein which goes through proteolytic processing via proteases encoded in the 
genome 1. In CVB3 this is mediated by the 2A (2Apro) and 3C (3Cpro) proteases 1. Once the 
polyprotein is cleaved into its main subunits, negative strand RNA synthesis occurs. This 
negative stranded RNA synthesis acts as a template for positive RNA strand synthesis. The 
CVB3 genome encodes a VPg (virus protein genome linked) that is covalently attached to the 
five-prime end of the positive stand RNA and acts as a primer during RNA synthesis, allowing 
VPg to facilitate this positive strand RNA synthesis 1,49. When there is an abundant amount of 
positive stranded RNA, these genomes are encapsidated via the virion protein (VP) structural 
proteins. The cell then goes through cell lysis via viroporins and subsequent viral release 1,2,49,50. 
As mentioned, polyamines play critical roles in these viral processes, but their exact mechanism 
of action, for RNA viruses, remains unclear. Therefore, if passaging techniques are utilized with 
DFMO as the drug condition, the potential mutations may give a better understanding as to how 
polyamines contribute to infectivity in the case of CVB3.  
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Figure 3. Coxsackievirus B3 Viral Life Cycle. Enterovirus life cycle diagram, beginning at 
viral binding and uptake through cell lysis and subsequent viral release. Image adapted and 
modified from van der Linden et. al. (2015) 1. Permissions obtained from van der Linden et. al.  
 
 
Enterovirus Genome Processing and Proteases 
  
 CVB3 proteases 2A (2Apro) and 3C (3Cpro) are crucial for replication and infectivity, 
cleaving both viral and host proteins 1,51–59. 2A facilitates the initial viral cleavage of the 
polyprotein, cleaving the P1 from the P2 protein segment 1, effectively separating the structural 
proteins from the replication proteins. The 3C protease is responsible for the bulk of the 
polyprotein cleavage events. These cleavage events are shown below in Figure 4 1. Interestingly, 
3C also acts as protease in a complex with 3D polymerase, called the 3CD polyprotein 60. 
Although these proteases are vitally important in several infection cycle steps, the regulation of 
their activities and their overlapping and unique functions have yet to be fully elucidated. They 
are, however, important potential drug targets 61–63. 
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Figure 4. Proteolytic Processing of the 2A and 3C CVB3 Proteases. Viral proteolytic 
processing mediated by the 2A and 3C CVB3 proteases. Image adapted and modified from van 
der Linden et. al. (2015) 1. Permissions obtained from van der Linden et. al. 
 
 The importance targeting these viral proteases in drug therapy is also highlighted by the 
protease’s capacity to cleave several host proteins. This includes translation factors, immune 
effectors and signaling molecules. Both proteases cleave these factors in order to provide a 
proviral environment for effective viral infection. The known cellular targets include: MDA5, 
MAVS, eIF4G, DAP5, NFAT5 and zinc-finger antiviral protein 51–56. Melanoma differentiation-
associated protein 5 (MDA5) is a RIG-1-like receptor and has a pathogen- associated molecular 
pattern (PAMP) for dsRNA, which is specific to viral infections 51. Along those lines the 
mitochondrial antiviral protein (MAVS) and zinc-finger antiviral proteins both act to inhibit viral 
replication 51,56. The zinc-finger antiviral protein (ZAP) recruits cellular RNA degradation into 
the cytoplasm 55. Eukaryotic initiation factor 4G (eIF4G) initiates translation; cleavage initiates 
translation shut-off 52,53,64. Death-associated protein 5 (DAP5) is a translation initiation factor 
which mediates IRES- dependent translation 54. Meaning that the viral cleavage of either eIF4G 
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or DAP5 would halt host cell translation. Lastly, nuclear factor activated T-cells 5 (NFAT5) is 
turned on in osmotic stress 55. Cleavage of these proteins renders the cell unable to fight against 
viral infections and mount a productive immune response 55.  
Aims and Hypothesis 
Viral evolution, especially RNA viral evolution, can occur at an accelerated rate due to 
RNA virus’ lack of proof-reading activity and error prone polymerase. This is the case for the 
positive sense single-stranded RNA virus, Coxsackievirus Type B (CVB3), a known public 
health threat. Previous work from our lab has shown that passaging CVB3 in polyamine-depleted 
conditions mutations occur in the protease regions of the CVB3 genome. Interestingly, there has 
never been an established link between polyamines and viral protease activity. Therefore, the 
overall hypothesis of this work is that CVB3 protease activity is modulated by polyamines and 
CVB3 gains resistance to polyamine depletion via mutation of its proteases. The goal of this 
project is to clarify the interaction occurring between polyamines and viral proteolytic activity 
through the following aims.  
Our first aim is to fully characterize these mutants that resulted from previous passages of 
CVB3 in the presence of difluoromethylornithine (DFMO). Our goal here is to measure how 
CVB3 protease mutations affect viral fitness and resistance to other antivirals. We hypothesized 
that these mutations confer resistance to other polyamine depleting drugs, such as 
diethylnorspermidine (DENSpm), that these mutations are stable, and that their viral fitness may 
be altered due to the mutations.  
Our second aim is to determine the effect of polyamines on protease activity. We 
hypothesize that polyamines play a direct role in modulating protease activity. Our goal is to 
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elucidate how polyamines contribute to CVB3 protease activity both utilizing a protease assay 
and monitoring a cellular cleavage event.  
Our third aim is to investigate whether these mutants confer resistance to polyamine 
depletion via affecting protease activity. Our goal is to measure protease activity via Western 
Blot and protease assay and determine whether our protease mutants could cleave their targets in 
polyamine depleted conditions.   
This work highlights the evolution of Coxsackievirus in the presence of novel antivirals, 
as well as the mechanistic features of the viral protease and ways in which clinicians can combat 
this resistance. In addition, we will clarify CVB3 protease functions and how it is modulated by 
polyamines.  
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CHAPTER TWO: MATERIALS AND METHODS 
 
Cell Culture 
Cells were maintained at 37⁰C in 5% CO2, in Dulbecco’s modified Eagle’s medium (DMEM; 
Life Technologies) with bovine serum and penicillin-streptomycin. The following reagent was 
obtained through BEI Resources, NIAID, NIH: Vero cells, Kidney (African green monkey), 
Expressing Luciferase (Luc2P), NR-10385 which were supplemented with 10% new-born calf 
serum (NBCS; Thermo-Fischer). HeLa and 293T cells, kindly provided by Dr. Ed Campbell, 
were supplemented with 10% fetal bovine serum (FBS; Thermo-Fischer). 
Generation of CVB3 and 2A29K and 3C52R Mutants 
 CVB3 (Nancy strain)65 was derived from the first passage of the virus in Vero cells after 
rescue from the infectious clone. Briefly, CVB3 infectious clone 66 was linearized with SapI 
(New England Biolabs [NEB]) and used to generate RNA in vitro (NEB). This RNA was 
transfected into Vero cells to recover the virus. The 2A29K and 3C52R mutant viruses were 
generated via site-directed mutagenesis of the wildtype CVB3 plasmid using the primers listed in 
Table 1 via mutagenic PCR with Phusion polymerase (Thermo-Fisher).   
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Table 1. Primers used in this study. 
Protease/Target Function Sense Sequence 
2A 
Clone F 5’- 
GCTGCGGCCGCAGGCGCATTTGGACAACAAT
CAGG – 3’ 
Clone R 5’- 
GCTTCTAGATTACTGTTCCATTGCATCATCCTT
CCAG- 3’ 
Sequenc
e 
F 5’- CATGTCAAAGCGTGGATACCTAGAC - 3’ 
Sequenc
e 
R 5’- GCACATGGGATTGGTATCTCCTGGG – 3’ 
qPCR F 5’- CATGTCAAAGCGTGGATACCTAGAC - 3’ 
qPCR R 5’- GCACATGGGATTGGTATCTCCTGGG – 3’ 
3C 
Clone F 5’- 
GTTGCGGCCGCTGGCCCTGCCTTTGAGTTCGC
CG -3’ 
Clone R 5’- 
GCGTCTAGATTATTGCTCATCATTGAAGTAGT
GTTTG -3’ 
Sequenc
e 
F 5’- TATACAGGAGTGCCCAACCAGAAGC – 3’ 
Sequenc
e 
R 5’- GAATGTACATGTTGGGAAACTTGCT – 3’ 
qPCR F 5’-AGGGCGAGATCAATCACATTAG-3’ 
qPCR R 5’-CTCTGCTGTTGCCTCACTATC-3’ 
2A ProTarget 
Clone F 5’ – 
GATCCATGACCAACACCGGCGCGTTTGGCTA
A – 3’ 
Clone R 5’ – 
AGCTTTAGCCAAACGCGCCGGTGTTGGTCATG 
– 3’ 
3C ProTarget 
Clone F 5’ – GATCCGCGATGGAACAGGGCTAA – 3’ 
Clone R 5’- AGCTTTAGCCCTGTTCCATCGCG – 3’ 
2A/3C 
ProTarget 
Sequenc
e 
F 5’-GTAGTACAGACTGGAAAATATC-3’ 
 
Infection and Enumeration of Viral Titers 
CVB3 (Nancy strain) 65 was derived from the first passage of virus in Vero cells (NR-10385), 
which were obtained through BEI Resources, National Institutes of Allergy and Infectious 
Diseases, National Institutes of Health (NR-10385).  For all infections, DFMO and DENSpm 
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were maintained throughout infection as designated below. Viral stocks were maintained at -
80⁰C. For infection, virus was diluted in serum-free DMEM to a multiplicity of infection (MOI) 
of 0.1 on Vero cells, unless otherwise indicated. Viral inoculum was overlain on cells for 10 to 
30 minutes, and the cells were washed with 1X PBS before replenishment of media. 
Supernatants were collected from CVB3 infected cells at 24 hpi and 48hpi. Dilutions of cell 
supernatant were prepared in serum-free DMEM and used to inoculate confluent monolayer of 
Vero cells for 10 to 15 min at 37⁰C. Cells were overlain with 0.8% agarose in DMEM containing 
2% NBCS. CVB3 samples incubated for 2 days at 37⁰C. Following incubation, cells were fixed 
with 4% formalin and stained with crystal violet solution (10% crystal violet; Sigma-Aldrich). 
Plaques were enumerated and used to back-calculate the number of plaque forming units (pfu) 
per milliliter of collected volume. 
Mutant CVB3 Propagation 
Vero cells were treated with DFMO for four days prior to infection with CVB3 at MOI 0.1. After 
24h, 1/10th of the cell culture volume was used to inoculate the next virus passage. This process 
was continued for ten passages, at which time RNA was purified from the cellular supernatant, 
reverse transcribed, amplified using CVB3-specific primers, and Sanger sequenced. Sequences 
were aligned to CVB3 parental genome and mutants were confirmed by manual chromatogram 
verification. 
Drug Treatments 
Difluoromethylornithine (DFMO; TargetMol) and N1,N11-Diethylnorspermine (DENSpm; 
Santa Cruz Biotechnology) were diluted to 100x concentrations (100mM and 10mM, 
respectively) in sterile PBS. For DFMO treatments, cells were trypsinized (Zymo Research) and 
reseeded with fresh medium supplemented with 2% serum to allow for reattachment. Following 
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overnight incubation, cells were treated with 100 µM, 500 µM, 1 mM, or 2 mM DFMO. Cells 
were incubated with DFMO for 96 hours to allow for depletion of polyamines. For DENSpm 
treatment, cells were treated with 100 nM, 1 µM, 10 µM, 100 µM, and 1mM concentrations fo 
16 hours prior to infection. During CVB3 infection, media was collected and saved from the 
cells.  The same medium containing DFMO and DENSpm was then used to replenish the cells 
following infection. Cells were incubated at the appropriate temperature for the duration of the 
infection.  
DFMO and DENSpm Passages 
Vero cells were treated with either 500µM DFMO or 100µM DENSpm, or left untreated, for 96 
or 16hrs respectively. For the first passage, cells were infected at an MOI of 0.1, and 
supernatants were collected at 24hpi. For the blind passages, 50µL of supernatant was used to 
inoculate subsequent passages. For fixed-MOI passages, viral titers were determined, and the 
next passage was infected at an MOI of 0.1.  
RNA purification and cDNA synthesis 
Media was cleared from cells and Trizol reagent (Zymo Research) directly added. Lysate was 
then collected, and RNA was purified according to the manufacturer’s protocol utilizing the 
Direct-zol RNA Miniprep Plus Kit (Zymo Research). Purified RNA was subsequently used for 
cDNA synthesis using High Capacity cDNA Reverse Transcription Kits (Thermo-Fischer), 
according to the manufacturer’s protocol, with 10-100 ng of RNA and random hexamer primers. 
DFMO and DENSpm Sensitivity Assays 
Vero cells were treated with either 100µM to 2000µM DFMO for 4 days or 1µm to 100µM 
DENSpm for 16h prior to infection with CVB3 at an MOI of 0.1. At 24 hpi, supernatants were 
collected, and titers were determined via Vero cell plaque assay.  
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Stability and Fitness Assays 
To measure stability of the mutations, Vero cells were infected at an MOI of 0.1 with all of the 
viral mutants for 24h. Virus was then passed to new cells by transferring 50µL supernatant. After 
five passages, RNA was extracted and purified from supernatants and reverse transcribed. Sanger 
sequencing was used to determine whether mutations were stable over the passages by looking at 
the chromatograms and determining presence or absence of the mutant nucleotide. Fitness assays 
were similarly performed, but Vero cells were infected at an MOI of 0.1 with an equal 
combination of wild-type and mutant CVB3 and passaged five times. Fitness was determined via 
Sanger sequencing and analysis of the chromatogram to determine if the wild-type or mutant 
nucleotide was most abundant in the sample.  
Plaque Size Measurement 
To quantify the relative plaque sizes of the different CVB3 mutants, Vero cells were seeded in 
10 cm dishes and grown to confluence in 10% Fetal Bovine Serum and DMEM. Approximately 
30 plaque-forming units (PFU) of each mutant was diluted in a 2.5 mL inoculum of serum-free 
DMEM. The media on the Vero cells was aspirated and replaced with the 2.5 mL inoculum 
containing the virus. The inoculum was incubated on the cells for approximately 30 min at 37 
◦C. After 30 min, an overlay of 8 mL 0.8% agarose was added to each dish. The dishes were 
incubated at 37 ◦C for 2 days to allow plaque formation. The cells were fixed with 4% formalin 
and the agarose plugs removed. The fixed cells were stained with crystal violet. Plaque size was 
determined using ImageJ software (Version 1.51k).67 
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Protease Plasmid Cloning 
Primers were designed to target either the wild-type 2A or 3C protease in the CVB3 genome. 
CVB3 plasmids containing either the 2A mutant protease or 3C mutant protease were used to 
clone the mutant proteases. To target the 2A and 2A mutant proteases, the primers included SacI 
and XbaI recognition sites (Table 1). Primers against the 3C and 3C mutant proteases included 
NotI and XbaI recognition sites. Protease sequences were amplified via PCR and cloned into the 
pFLAG-CMV-LAP1 vector with either the restriction enzyme pair SacI/XbaI or NotI/XbaI for 
2A and 3C respectively. Clones were verified by sequencing (GenScript). Oligonucleotide 
sequences corresponding to the amino acid sequence for the wild-type and mutant 2A and 3C 
protease targets were designed and cloned into the pGlo-3F vector and verified by sequencing 
(GenScript). 
Transfections 
293T cells were plated at 80%–90% confluency and either treated with 100 µM, 500 µM, 
1000µM or 2000 µMDFMO for 4-days or left untreated. The plasmids were then transfected in 
the combinations described in the figures, according to the manufacturer’s protocol, using 
LipoD293 (SignaGen Laboratories). The transfection was incubated at 37◦C for 24h. 
Luciferase Protease Assay 
293T cells were treated with either 100µM, 500µm, 1000µm, or 2000µm DFMO for 4 days or 
left untreated. They were then transfected using LipoD293 (SignaGen Laboratories) with the 2A 
substrate alone, 3C substrate alone, 2A substrate plus the 2A WT protease or 2A mutant 
protease, or the 3C substrate plus the 3C WT protease or the 3C mutant protease. For luciferase 
assays, cells were combined with firefly (Bright-Glo; Promega) followed by subsequent Renilla 
(Stop and Glo; Promega) luciferase substrate 24h post-transfection. Luciferase assays were 
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performed according to the manufacturer’s recommendations (Promega) and results were 
measured via the Veritas Microplate Luminometer (Turner BioSystems).   
Western Blot 
Samples were collected with Bolt LDS Buffer and Bolt Reducing Agent (Invitrogen) and run on 
polyacrylamide gels. Gels were transferred using the iBlot 2 Gel Transfer Device (Invitrogen). 
Membranes were probed with primary antibodies for eIF4G, (1:1000, Santa Cruz 
Biotechnology), GAPDH (1:1000, Santa Cruz Biotechnology), and β-actin (1:5000, Santa Cruz 
Biotechnology). Membranes were treated with SuperSignal West Pico PLUS Chemiluminescent 
Substrate (ThermoFisher Scientific) and visualized on ProteinSimple FluorChem E imager.   
Statistical Analysis 
Prism 6 (GraphPad) was used to generate graphs and perform statistical analysis. For all 
analyses, one-tailed Student’s t test was used to compare groups, unless otherwise noted, with a 
p= 0.05. For tests of sample proportions, p values were derived from calculated Z scores with 
two tails and a p= 0.05. 
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CHAPTER THREE: RESULTS 
 
Fixed Passages of CVB3 
Previous fixed passages of CVB3 in the presence of DFMO resulted in 2 mutations in the 
protease region of CVB3. These passages were done in a controlled manner, infecting the 
subsequent cells with a multiplicity of infection (MOI) of 0.1 and increasing the concentration of 
drug with each subsequent passage (Figure S1). This method forces bottlenecking. It is also 
important to note that, along with the drug-treated condition, untreated cells were passaged with 
CVB3 in a similar manner. These untreated cells act as a control: if there are mutations in 
passaged virus from the nontreated conditions and the same mutations show up in our drug 
treated conditions, then it is reasonable to assume that those mutations are occurring due to the 
process of passaging, not as a result of the drug. Therefore, only mutations that occur in the drug 
treated conditions and not in the untreated conditions were considered for further investigation. 
At passage five, the virus was tested for its susceptibility to DFMO treatment. Vero cells were 
treated with increasing concentrations of DFMO and the percent replication of the virus was 
measured by dividing the samples by the NT control in their respective concentrations of DFMO.  
(Figure S2). The virus passaged in the presence of DFMO has a significantly higher percent 
replication rate. This is indicative of intrinsic resistance to DFMO treatment at passage five.The 
mutations we studied further were in the protease region of the CVB3 genome: Q29K in the 2A 
protease and Q52R in the 3C protease. We then cloned these mutations in the CVB3 parental 
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 strain using mutagenic PCR. In addition to the 2AQ29K and 3CQ52R mutant, a 2AQ29K3C 
Q52R double mutant was also generated. After confirming the presence of these mutations, we 
generated infectious virus via transfection and measured virus titer by plaque assay over 
several rounds of replication, seen in Figure 1.  
Assessing the Mutants Resistance to DFMO 
To determine if these resultant CVB3 mutants were resistant to DFMO, Vero cells were 
treated with 500µM DFMO 4-days prior to CVB3 infection or left untreated, then infected at an 
MOI of 0.1 with wild-type CVB3 or mutant CVB3.  The supernatant was collected from these 
cells over a time course and CVB3 titers were determined via viral plaque assay (Figure 5).  All 
viruses in untreated conditions had similar growth kinetics even with the protease mutation. This 
is highlighted by the similar viral titers of the mutants to WT in NT condition (teal markers). In 
DFMO-treated cells the wild-type CVB3 exhibited significant reductions in titer, which persisted 
to 72hpi. When looking at the mutants vs the WT in DFMO treated conditions (orange markers) 
the protease mutants (either alone or in combination) exhibited a partial rescue in viral titer 
compared to the wild-type virus.  
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Figure 5. Growth Kinetics of Both the WT and Mutant Viruses in NT and DFMO Treated 
Conditions. Vero cells were either treated with DFMO for 4 days or left untreated, then infected 
at an MOI of 0.1 with either WT CVB3 or one of the mutant viruses. Growth kinetics were 
observed via viral titer from 16-72 hpi. Error bars represent ± 1 SEM 
 
To quantify resistance, we measured viral titers of wild-type and the protease mutants in 
untreated and DFMO pre-treated conditions over a range of concentrations (Figure 6). Vero 
cells, in both the pre-treated and untreated conditions, were infected at an MOI of 0.1 and viral 
titers were measured at 24hpi. Figure 6 displays that WT virus has significantly higher 
sensitivity to DFMO conditions (evident by the drop in viral titer) compared to the 2AQ29K, 
3CQ52R, and the 2AQ29K3CQ52R mutants. These mutants exhibit partial resistance, indicated by the 
increased viral titers in DFMO-treated conditions. We then measured percent replication by 
dividing the titer in DFMO treatment conditions at 500µm by the titer in untreated conditions 
(Figure 7). We observed that all the mutants showed higher replication than that of the WT 
virus, suggesting that the mutant viruses could replicated better than WT in DFMO-treated 
conditions. Individually, the protease mutations showed similar levels of replication in these 
conditions.  
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Figure 6. Testing the Mutants Susceptibility to DFMO Treatment.Vero cells were either 
treated with 500µM, 1mM or 5mM DFMO for 4d or left untreated. Cells were infected with the 
WT or mutant viruses at an MOI of 0.1, 24 hpi viral titers were enumerated. Error bars represent 
± 1 SEM 
 
Figure 7. Determining the Percent Replication of the Mutants in DFMO Conditions 
Compared to WT.Vero cells were treated with 500µM DFMO and infected at an MOI of 0.1 
with the WT or mutant viruses. At 24 hpi viral titers were enumerated. The results are the titers 
of each respective virus divided by the titer in untreated conditions. Error bars represent ± 1 
SEM 
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Determining the Stability and Fitness of the Mutants 
In order to determine the stability of these mutants, WT CVB3 as well as the 2AQ29K, 
3CQ52R, and the 2AQ29K3CQ52R mutants were passaged on untreated Vero cells for five passages. 
At the end of the fifth passage, supernatants were collected, RNA was purified, reverse 
transcribed, and used for  Sanger sequencing the mutations of interest (Figures 8-10). We found 
that all of the mutations were present after the fifth passage 
  
  
 
Figure 8. Analysis of the Stability of the 2AQ29K mutant. The 2AQ29K mutant was passaged in 
untreated Vero cells for a total of 5 passages, RNA was then extracted from the supernatant, 
purified, reverse transcribed than sent off for sequencing. A) Comparative look of the passaged 
2AQ29K mutant sequence aligned with the WT 2A sequence utilizing serial cloner. Octothorp (#) 
indicate differences in sequence. Highlighted sequence is the 2A mutation. B) Comparative look 
of the passaged 2AQ29K mutant sequence aligned with the WT sequence utilizing Benchling 
software. Highlighted portion is the 2A mutation site. Red nucleotides indicate differences from 
WT sequence. 
A 
B 
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Figure 9. Analysis of the Stability of the 3CQ52R mutant. The 3CQ52R mutant was passaged 
in untreated Vero cells for a total of 5 passages, RNA was then extracted from the supernatant, 
purified, reverse transcribed than sent off for sequencing. A) Comparative look of the passaged 
3CQ52R mutant sequence aligned with the WT 3C sequence utilizing serial cloner. Octothorp (#) 
indicate differences in sequence. Highlighted sequence is the 3C mutation. B) Comparative look 
of the passaged 3CQ52R mutant sequence aligned with the WT sequence utilizing Benchling 
software. Highlighted portion is the 3C mutation site. Red nucleotides indicate differences from 
WT sequence. 
 
 
A 
B 
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Figure 10. Analysis of the Stability of the 2AQ29K 3CQ52R mutant at the 3CQ52R Mutation 
Site. The 2AQ29K3CQ52R mutant was passaged in untreated Vero cells for a total of 5 passages, 
RNA was then extracted from the supernatant, purified, reverse transcribed than sent off for 
sequencing. The double mutant was sequenced at the 3C mutation site. A) Comparative look of 
the passaged 2AQ29K 3CQ52R mutant sequence aligned with the WT 3C sequence utilizing serial 
cloner. Octothorp (#) indicate differences in sequence. Highlighted sequence is the 3C mutation. 
B) Comparative look of the passaged 2AQ29K 3CQ52R mutant sequence aligned with the WT 
sequence utilizing Benchling software. Highlighted portion is the 3C mutation site. Red 
nucleotides indicate differences from WT sequence. 
 
Viral fitness was determined utilizing a similar protocol as the stability assay, with the 
exception that each virus was mixed with wild-type CVB3 at a 1:1 ratio. This mixture was then 
used to inoculate Vero cells for 24h and passaged for five rounds. At and at the end of the fifth 
passage, supernatants were collected, RNA was purified and reverse transcribed, and sent off for 
A 
B 
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sequencing at the mutation sites (Figures 11-13). Through analyses of the chromatogram, we 
found that no mutant had a fitness advantage over the WT virus. This is due to the absence of 
one nucleotide dominating. The presence of a mixed population, two peaks of nucleotides, at the 
site of the mutation is indicative of no overall fitness advantage. The mixed population shows us 
that both viruses were present at the 5th passage, meaning neither virus outcompeted the other. It 
is important to note that this result is strictly qualitative, and is not measure of the abundance of 
one nucleotide over the other. This result was recapitulated when the plaque sizes of the mutants 
were compared to wild-type (Figure 14). 
 
Figure 11. Analysis of the Fitness of the 2AQ29K Mutant Virus vs. WT. Mutant 2AQ29K fitness 
was measured utilizing a competition assay. Mutant 2AQ29K was mixed with WT CVB3 in a 1:1 
ratio, this mixture was used to infect untreated Vero cells and passaged 5 times. The supernatant 
was then collected, RNA was extracted and purified, reverse transcribed and then sequenced at 
the 2A mutation site. Results were analyzed via chromatograph. The highlighted portion is the 
nucleotide site that is mutated in 2AQ29K. 
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Figure 12. Analysis of the Fitness of the 3CQ52R Mutant Virus vs. WT. Mutant 3CQ52R fitness 
was measured utilizing a competition assay. Mutant 3CQ52R was mixed with WT CVB3 in a 1:1 
ratio, this mixture was used to infect untreated Vero cells and passaged 5 times. The supernatant 
was then collected, RNA was extracted and purified, reverse transcribed and then sequenced at 
the 3C mutation site. Results were analyzed via chromatograph. The highlighted portion is the 
nucleotide site that is mutated in 3CQ52R. 
 
 
 
 
Figure 13. Analysis of the Fitness of the 2AQ29K 3CQ52R Mutant Virus vs. WT. Mutant 2AQ29K 
3CQ52R fitness was measured utilizing a competition assay. Mutant 2AQ29K 3CQ52R was mixed 
with WT CVB3 in a 1:1 ratio, this mixture was used to infect untreated Vero cells and passaged 
5 times. The supernatant was then collected, RNA was extracted and purified, reverse transcribed 
and then sequenced at the 2A mutation site. Results were analyzed via chromatograph. The 
highlighted portion is the nucleotide site that is mutated in 2AQ29K. 
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Figure 14. Determination of Viral Fitness via Plaque Assay. Untreated Vero cells were 
infected with both the WT and mutant viruses at an MOI of 0.1. A plaque assay was then 
performed to visualize, and the size of the plaques were measured. 
 
Evaluating the Mutants’ Resistance to DENSpm 
We next wanted to evaluate whether or not these mutations also confer resistance to other 
polyamine depleting drugs, such as diethylnorspermidine (DENSpm). DENSpm depletes 
polyamines through accelerating polyamine metabolism by acetylating spermidine and spermine, 
marking them for export. Vero cells were pretreated with 10µM DENSpm for 16h, or left 
untreated, the cells were then inoculated with wild-type CVB3, 2AQ29K, 3CQ52R, and the 
2AQ29K3CQ52R  mutants at an MOI of 0.1, after 24h the supernatant was collected and titered in 
order to determine PFU (Figure 15). Raw measures of viral titers show a slight rescue of the 2A 
mutant in the presence of DENSpm but this rescue of viral titer was complete when looking at 
both the 3C and 2A3C mutant.  
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Figure 15. Determining the Sensitivity of the Mutants in DENSpm Compared to NT. Vero 
cells were treated with 10µM DFMO or left untreated and infected at an MOI of 0.1 with the WT 
or mutant viruses. At 24 hpi viral titers were enumerated. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 
using Student’s t-test (n ≥ 3), comparing treated samples to untreated controls. Error bars 
represent ± 1 SEM 
 
When looking at the percent replication in DENSpm compared to untreated control all 
three of the mutants confer partial resistance to DENSpm, most notably the 3CQ52R and 
2AQ29K3CQ52R mutant which both reach about 60% replication in DFMO treated conditions 
compared to control. This suggests that the mutants were able to replicate 60x better in DFMO 
than the WT virus (Figure 16).  
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Figure 16. Determining the Percent Replication of the Mutants in DENSpm Conditions 
Compared to WT. Vero cells were treated with 10µM DFMO and infected at an MOI of 0.1 
with the WT or mutant viruses. At 24 hpi viral titers were enumerated. The results are the titers 
of each respective virus divided by the titer in untreated conditions. * p ≤ 0.05, ** p ≤ 0.01, *** 
p ≤ 0.001 using Student’s t-test (n ≥ 3), comparing treated samples to untreated controls. Error 
bars represent ± 1 SEM 
 
Passaging CVB3 in DENSpm 
Due to the 2AQ29K, 3CQ52R, and the 2AQ29K3CQ52R mutants being resistant to DENSpm, 
we wanted to determine if CVB3 would gain resistance to DENSpm if passaged similarly to the 
original passages with the exception of utilizing DENSpm rather than DFMO. Vero cells were 
either pre-treated with 10µM DENSpm or left untreated for 16h and then inoculated with CVB3 
at an MOI of 0.1. As mentioned earlier, concentration of DENspm was increased as passaging 
increased, and each new passage was infected at an MOI of 0.1 to promote bottlenecking. Along 
with the drug treated condition, untreated cells were also utilized for passaging as a control, as 
virus passaged in untreated conditions should not gain resistance to polyamine depletion. 
Supernatant was collected at 24h post-infection, viral titer was determined via plaque assay, and 
this new titer was then used to infect new Vero cells that had been pretreated with DENSpm at 
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10µM for 16h with an MOI of 0.1, DENSpm concentration was increased as passaging increased 
in order to encourage bottlenecking. This process was completed for a total of 10 passages. 
Through viral titer we observe that the CVB3 that was passaged in the presence of DENSpm had 
an increase of viral titer(Figure 17), suggestive of resistance. Figure 17 also shows a cyclical 
pattern, where viral titer drops and then rebounds in the next passage. It is possible that 
passaging in this way is producing defective virus, where after one passage the only viruses 
present are viruses that are extremely efficient at replication. The subsequent passage produces 
viruses that are not as efficient but are still able to infect non-treated cells and produce viable 
plaques. The next passage that is infected with this non-efficient virus cannot replicate as well in 
DENSpm treated conditions, therefore only the efficient viruses survive.  
 
 
Figure 17. Determining Resistance through Viral Titer. Vero cells were treated with 
DENSpm and infected with WT CVB3 at an MOI of 0.1, the virus was passaged through fixed 
passaging and viral titer was determined after each passage. Error bars represent ± 1 SEM 
 
We performed these passages with DENSpm in an uncontrolled manner as well – blind 
passaging. Vero cells were pretreated with 10µM DENSpm 16h before infection or left 
untreated, the cells were then infected at an MOI of 0.1. After 24h, 50µL of supernatant was used 
to inoculate new Vero cells that had previously been pretreated with 20µM DENSpm. This was 
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done until a total of 10 passages was reached. Increasing in concentrations of DENSpm were 
used in order to enhance bottlenecking, and the untreated cell passages act as a control. As virus 
passaged in untreated conditions should not gain resistance to polyamine depletion.  At the end 
of the 10th passage DENSpm sensitivity was investigated. This was done by treating cells with 
100µM DENSpm for 16h, inoculating cells with the passaged virus, and 24hpi viral titers were 
determined via plaque assay. As can be seen in Figure 18, after passage 10, the virus gained a 
partial resistance to DENSpm pretreatment, with untreated virus showing a 19.6x decrease in 
viral titer and the DENSpm treated virus having a 7x decrease in viral titer, compared to non-
treated conditions. This suggested the development of limited resistance in the DENSpm 
passaged virus.  
 
Figure 18. Determining Passaged Virus Sensitivity to DENSpm. Vero cells were treated with 
DENSpm and infected with WT CVB3 at an MOI of 0.1, the virus was passaged through blind 
passaging. After the 10th passage virus was collected and tested for its sensitivity to DENSpm. 
Vero cells were treated for 16hs with 100µM DENSpm and infected with the blind passaged 
virus. Error bars represent ± 1 SEM 
 
CVB3 Protease activity being Modulated by Polyamines 
Due to the 2AQ29K, 3CQ52R, and the 2AQ29K3CQ52R mutants developing resistance to polyamine 
depletion, we hypothesized that polyamines modulate protease activity. To directly measure 
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proteolytic activity with or without polyamines we generated a protease-sensitive dual luciferase 
reporter system. A schematic of which can be seen in Figure 19.  In this luciferase system, 
cleavage of a target sequence allows for firefly luciferase activity, which was normalized to a 
Renilla luciferase transfection control. This system has previously been established to examine 
viral proteases, but this has not been extended to CVB3 2A or 3C proteases 68–70. In order to 
generate this system, we cloned a 2A target sequence -MTNTGAFG - and a 3C target sequence 
– SAMEQG- into the firefly luciferase reporter 71. We also cloned the 2A and 3C CVB3 
proteases into the pCMV plasmid to drive robust protease expression.  These constructs were co-
transfected into 293T cells that had either been pre-treated with increasing concentrations of 
DFMO for 4days or left untreated. Firefly activity was measured as luminescence at 24h hpi and 
normalized to Renilla activity (Figure 20).  The data shows that with increasing concentrations 
of DFMO the proteolytic activity significantly decreases, indicative of viral proteases being 
reliant upon polyamines for functionality.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Depiction of the Protease Assay which Utilizes Luciferase Activity. The target 
substrate contains a protease recognition site, once recognized, the 2A or 3C protease cleaves 
said site and the substrate confers a conformational change which allows for robust luciferase 
activity. 
2A or 3C 
Protease 
Protease 
Recognition 
Site 
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Figure 20. Determining the Viral Proteases Sensitivity to DFMO Treatment. Utilizing the 
protease assay, viral protease activity was testing in a variety of DFMO concentrations. The 
results were normalized first to Renilla activity then to NT conditions.* p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.001 using Student’s t-test (n ≥ 3), comparing treated samples to untreated controls. 
Error bars represent ± 1 SEM 
 
In order to look at the protease activity in vitro, specifically the cellular targets of 2A and 3C, we 
treated cells with increasing doses of DFMO and DENSpm to deplete cellular polyamines. 
Following incubation with drug, cells were infected at an MOI of 10 for 24h, and cellular lysates 
were then collected for western analysis. Higher MOI was utilized in order to get robust cleavge 
of the cellular target.  Lysates were analyzed for the presence of cleaved eIF4G, a cellular target 
for the viral proteases (Figure 21). The data displayed shows that in infected cells, a distinct 
eIF4G band was present; however, in cells treated with either DFMO or DENSpm, the eIF4G 
cleavage is significantly inhibited.  
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Figure 21. Determining the Virus’s ability to Cleave Cellular Targets in Polyamine 
Depleting Drugs. Viral cellular target, eIF4G, cleavage was monitored in virally infected cells in 
the presence or absence of both DFMO and DENSpm. 
 
CVB3 Mutant Protease activity being resistant to polyamine depletion 
Due to mutations occurring in these protease regions, we hypothesized that these mutations may 
be able to maintain viral protease activity even in the absence of polyamines. In order to test this, 
we generated mutant 2AQ29K and 3CQ52R proteases through site-directed mutagenesis of our 
overexpression vectors. We then co-transfected these proteases and wild-type controls with our 
luciferase reporter system into 293T cells that had either been treated with 500µM DFMO for 
4days or left untreated. After 24h, we measured luciferase activity as luminescence and 
normalized to Renilla luciferase activity and to control cells transfected with the luciferase 
reporter alone (no protease) (Figure 22). It was observed that both the wild-type 2A protease as 
well as the 3C wild-type protease exhibited decreased protease activity in the presence of 
DFMO. However, both the 2AQ29K and 3CQ52R mutant had robust protease activity in both the 
nontreated and DFMO treated conditions. It can also be seen that the mutant 3C protease has 
higher proteolytic activity than the wild-type but this same phenomenon is not seen in the 2A 
protease.   
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Figure 22. Determining the Viral Mutants Ability to Resist DFMO Treatment. Wildtype and 
Mutant CVB3 protease activity was monitored via the protease assay in either untreated or 
polyamine depleted conditions.  The results were normalized, first to the renilla control, then to 
the no protease conditions.* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 using Student’s t-test (n ≥ 3), 
comparing treated samples to untreated controls. Error bars represent ± 1 SEM 
 
We further hypothesized that mutant protease activity may enhance proteolytic cleavage of a 
cellular target during viral infection to enhance virus replication. To investigate this, we treated 
Vero cells with 500µM DFMO for 4d or left cells untreated and then infected at an MOI of 10 
for 24h. Cell lysates were collected and analyzed for cleavage of eIF4G (Figure 23). In untreated 
cells, we observed significant cleavage of eIF4G with WT infection and similar levels of 
cleavage with infection of the 2AQ29K, 3CQ52R, and the 2AQ29K3CQ52R   mutants. However, with 
DFMO treatment, eIF4G was significantly reduced in WT CVB3 virus as was previously 
observed, but proteolytic cleavage in the mutant viruses was significantly higher than that of 
WT.   
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Figure 23. Elucidating the Mutant Virus’s ability to Cleave Cellular Targets (eIF4G) in the 
Presence of DFMO. The ability of the mutant and wildtype viruses ability to cleave eIF4G in 
the presence of DFMO was monitored via western blot. 
 
A similar experiment was done using DENSpm as the polyamine depleting drug (Figure S4). 
We observed cleavage of eIF4G was only partially rescued in mutant viruses. Nonetheless, the 
cleavage was less pronounced than in the DFMO treated conditions. This further suggests that 
DENSpm might disrupt the cell differently than DFMO, given that DENSpm leaves putrescene 
in the cell due to its mechanism of action, which can be seen in Figure 2.  
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CHAPTER FOUR: DISCUSSION 
Escape Mutants 
 Viral escape mutants are an important tool in studying multiple facets of RNA virus 
replication 72. Here, our utilization of drug treatment to produce these viral escape mutants 
provides a better understanding as to how the virus is able to mutate in order to resist antiviral 
treatment, which, in turn, allows us to understand mechanisms as to how the antiviral is actually 
affecting the virus. In the case of drugs such as DFMO and DENSpm, escape mutants offer a 
better understanding not only of how these drugs are affecting the virus, but also how 
polyamines, specifically, are interacting with RNA viruses. It also provides insight as to what 
stage in the viral lifecycle polyamines are having a direct role. Subsequently, passaging gives us 
an understanding as to what mutations are necessary for CVB3 to gain resistance to polyamine 
depletion. Previously, chikungunya virus escape mutants from DFMO treatment, were 
characterized and found to confer resistance when simultaneously present in the virus 48. Unlike, 
CHIKV, we found that CVB3 gains resistance to DFMO treatment from a single mutation in 
either protease. Although we cannot determine whether polyamines help viral protease activity 
against a specific target, we observe that these mutations help viral infection in an otherwise 
antiviral environment. Determining the specifics of this interaction is an important area of study. 
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Characterization of Escape Mutants 
 
 Passaging CVB3 in the presence of DFMO resulted in two mutations, both of which 
involved changing from a neutral glutamine residue to a positively charged lysine or arginine. 
Interestingly, we observed similar amino acid changes from our CHIKV passages 48, where a 
glycine to arginine mutation was observed in the nsP1 region of the viral genome. Polyamines 
are positively charged molecules at a physiological pH, therefore, the appearance of positively-
charged amino acids due to polyamine depleted conditions suggests that these mutations are due 
to viral compensation from losing polyamines in the environment. The mutations we observe in 
the 2A and 3C protease region of CVB3 are not in the active site of either enzyme 65,73. This 
suggests that these amino acids, with their positive charge, are affecting the active site of these 
enzymes allosterically. How exactly this is occurring remains unknown.  
 Importantly, as was alluded to previously, these single mutations in the protease confer 
resistance to both DFMO and DENSpm treatment. There is a significant rescue of viral titer, 
which can be seen in our sensitivity assays. These data suggest that this single amino acid 
change, to a positively charged residue is enough to partially rescue viral infectivity.  
 When comparing the fitness of mutant viruses to WT we saw no fitness advantage of one 
over the other, contrary to what was seen in CHIKV mutants 48. The specific infectivity of the 
mutations was not affected either, as can be seen in Supplemental Figures 3 A, B and C. 
However, these mutations can withstand polyamine-depleted conditions. This result suggests that 
even if the virus were to emerge, the mutation may not fix a population if not exposed to DFMO.  
DENSpm Escape Mutants 
 We also looked at viral escape mutants utilizing DENSpm as the polyamine depleting 
vehicle rather than DFMO. After 10 passages, both through controlled, fixed MOI passaging, 
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and blind passaging, viruses that survived exhibited a partial resistance to DENSpm treatment. 
Further testing will need to be done in order to determine the mutation(s) that arose as well as 
whether this also conferred resistance to DFMO treatment.  
Polyamines and Viral Protease Activity 
 The placement of the mutations as well as our data suggests a novel function of 
polyamines in protease activity. Although it has been observed that polyamines contribute to 
protease activity 74 of plant and eukaryotic proteases, a function for polyamines in viral protease 
activity has not been described. Specifically, spermidine interacts with and activates the activity 
of mammalian chymotrypsin75. The broader implications of polyamines and protease activity, 
especially related to viral protease activity, have not been explored beyond this study. Our data 
supports the idea that polyamines contribute to the function of viral proteases 76.  
In general, targeting polyamines synthesis as a therapeutic method offers great potential 
as the availability of FDA-approved molecules like DFMO allows for the potential of inhibition 
of this pathway that is key for successful viral infection. Again, the appearance of these 
resistance mutation from single amino acid changes necessitate combination therapy in order to 
combat this resistance emerging, especially considering the fitness of these mutant viruses are 
not greater than that of WT in non-DFMO treated conditions.  
  Overall these data suggest that these mutations are not enhancing protease activity, at 
least in the case of 2A, and therefore must be extremely specific to polyamines. Interestingly, it 
seems that DFMO and DENSpm, although both polyamine depleting drugs, might disturb viral 
replication in different ways, as illustrated by Supplemental Figure 4. The putrescene that is left 
in the system from DENSpm treatment, due to the mechanism of action of DENSpm as shown in 
Figure 2, might have some effect on these mutants and their ability to infect cells. With this in 
   
41 
mind, examining and characterizing the viral escape mutants from the DENSpm passages will be 
an interesting area to study and follow-up on in order to determine this complex relationship. 
 Overall this thesis offers insight and new evidence as to how polyamines contribute to 
viral protease activity and suggests a potential target for antiviral therapy to combat CVB3 and 
potentially other viruses.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX: SUPPLEMENTAL FIGURES 
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Figure S1. CVB3 Develops Resistance to Polyamine Depletion Over Passages with 
Polyamine-Depleting Molecules. Vero-E6 cells were left untreated of treated with 500µM 
DFMO for four days prior to infection with CVB3 at an MOI of 0.1. Virus was collected at 24hpi 
and used to infect the next passage. Viral Titers were determined via plaque assay. Error bars 
represent ± 1 SEM 
 
 
 
 
 
 
Figure S2. After Passage Five CVB3 Shows Resistance to Polyamine Depletion. CVB3 
passaged five times over Vero-E6 cells, either treated with 500 μM DFMO or untreated, were 
used to infect Vero cells treated with increasing doses of DFMO for 24 hpi. Viral Titers were 
determined via plaque assay. Error bars represent ± 1 SEM 
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Figure S3. Specific Infectivity is not Altered with Protease Mutation. Vero cells were 
infected with WT and mutant CVB3 for 24hr at which time viral titers were determined by 
plaque assay (A) and viral genomes in cell supernatant were determined via qPCR (B). The ratio 
of genomes-to-PFU (C)  was calculated by dividing he relative genomes in (B) by the titer in 
(A). Error bars represent ± 1 SEM 
 
 
 
 
Figure S4. Assessing the Mutant Virus’s ability to Cleave Cellular Targets (eIF4G) in the 
Presense of DENSpm.  The ability of the mutant and WT viruses ability to cleave eIF4G in the 
presense of DENSpm, another polyamine depleting drug, was monitored via western blot. 
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